NCT00413335View on ClinicalTrials.gov

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

December 31, 2008

Conditions
ObesityImpaired Glucose ToleranceType 2 Diabetes Mellitus
Interventions
DRUG

Rosiglitazone

2mg to begin then 4mg, twice daily for 4 months

DRUG

Placebo

Subject receives placebo.

Trial Locations (1)

06520

Yale School of Medicine, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT00413335 - Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth | Biotech Hunter | Biotech Hunter